The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 11 Apr 2006
doi: 10.1242/jcs.02887
Research Article
Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin
Yazmín Macotela,
Manuel B. Aguilar,
Jessica Guzmán-Morales,
José C. Rivera,
Consuelo Zermeño,
Fernando López-Barrera,
Gabriel Nava,
Carlos Lavalle,
Gonzalo Martínez de la Escalera,
and
Carmen Clapp*
* Author for correspondence (e-mail: clapp{at}servidor.unam.mx)
The 16 kDa N-terminal fragment of prolactin (16K-prolactin) is a potent antiangiogenic factor. Here, we demonstrate that matrix metalloproteases (MMPs) produced and secreted by chondrocytes generate biologically functional 16K-prolactin from full-length prolactin. When incubated with human prolactin at neutral pH, chondrocyte extracts and conditioned medium, as well as chondrocytes in culture, cleaved the Ser155-Leu156 peptide bond in prolactin, yielding - upon reduction of intramolecular disulfide bonds - a 16 kDa N-terminal fragment. This 16K-prolactin inhibited basic fibroblast growth factor (FGF)-induced endothelial cell proliferation in vitro. The Ser155-Leu156 site is highly conserved, and both human and rat prolactin were cleaved at this site by chondrocytes from either species. Conversion of prolactin to 16K-prolactin by chondrocyte lysates was completely abolished by the MMP inhibitors EDTA, GM6001 or 1,10-phenanthroline. Purified MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13 cleaved human prolactin at Gln157, one residue downstream from the chondrocyte protease cleavage site, with the following relative potency: MMP-8>MMP-13>MMP-3>MMP-1=MMP-2>MMP-9. Finally, chondrocytes expressed prolactin mRNA (as revealed by RT-PCR) and they contained and released antiangiogenic N-terminal 16 kDa prolactin (detected by western blot and endothelial cell proliferation). These results suggest that several matrix metalloproteases in cartilage generate antiangiogenic 16K-prolactin from systemically derived or locally produced prolactin.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera
Peptide Hormone Regulation of Angiogenesis
Physiol Rev,
October 1, 2009;
89(4):
1177 - 1215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tarin, M. Gomez, E. Calvo, J. A. Lopez, and C. Zaragoza
Endothelial Nitric Oxide Deficiency Reduces MMP-13-Mediated Cleavage of ICAM-1 in Vascular Endothelium: A Role in Atherosclerosis
Arterioscler Thromb Vasc Biol,
January 1, 2009;
29(1):
27 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Clapp, S. Thebault, E. Arnold, C. Garcia, J. C. Rivera, and G. M. de la Escalera
Vasoinhibins: novel inhibitors of ocular angiogenesis
Am J Physiol Endocrinol Metab,
October 1, 2008;
295(4):
E772 - E778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Forster, D. Hilfiker-Kleiner, A. A. Ansari, J. B. Sundstrom, E. Libhaber, W. Tshani, A. Becker, A. Yip, G. Klein, and K. Sliwa
Reversal of IFN-{gamma}, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy
Eur J Heart Fail,
September 1, 2008;
10(9):
861 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Dean, G. S. Butler, Y. Hamma-Kourbali, J. Delbe, D. R. Brigstock, J. Courty, and C. M. Overall
Identification of Candidate Angiogenic Inhibitors Processed by Matrix Metalloproteinase 2 (MMP-2) in Cell-Based Proteomic Screens: Disruption of Vascular Endothelial Growth Factor (VEGF)/Heparin Affin Regulatory Peptide (Pleiotrophin) and VEGF/Connective Tissue Growth Factor Angiogenic Inhibitory Complexes by MMP-2 Proteolysis
Mol. Cell. Biol.,
December 15, 2007;
27(24):
8454 - 8465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee
16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway
Cancer Res.,
November 15, 2007;
67(22):
11045 - 11053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Erdmann, A. Ricken, C. Merkwitz, I. Struman, R. Castino, K. Hummitzsch, F. Gaunitz, C. Isidoro, J. Martial, and K. Spanel-Borowski
The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle
Am J Physiol Endocrinol Metab,
November 1, 2007;
293(5):
E1365 - E1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ge, C. A. Fernandez, M. A. Moses, and D. S. Greenspan
Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor
PNAS,
June 12, 2007;
104(24):
10010 - 10015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Piwnica, I. Fernandez, N. Binart, P. Touraine, P. A. Kelly, and V. Goffin
A New Mechanism for Prolactin Processing into 16K PRL by Secreted Cathepsin D
Mol. Endocrinol.,
December 1, 2006;
20(12):
3263 - 3278.
[Abstract]
[Full Text]
[PDF]
|
|
|
© The Company of Biologists Ltd 2006
